Lipella director Lori Birder resigns from board

Lipella Pharmaceuticals Inc. reported that board member Dr. Lori A. Birder resigned from its Board of Directors, effective immediately on February 3, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Lipella Pharmaceuticals Inc. reported that board member Dr. Lori A. Birder resigned from its Board of Directors, effective immediately on February 3, 2026. The company stated that her resignation was not due to any disagreement regarding its operations, policies, or practices, indicating a routine governance change rather than a dispute-driven departure.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lipella Pharmaceuticals Inc. (LIPO) disclose in this 8-K filing?

Lipella Pharmaceuticals disclosed that Dr. Lori A. Birder resigned from its Board of Directors effective February 3, 2026. The company emphasized that her resignation was not due to any disagreement about its operations, policies, or practices, suggesting an orderly governance change.

Who resigned from the Lipella Pharmaceuticals (LIPO) Board of Directors?

Dr. Lori A. Birder resigned from the Board of Directors of Lipella Pharmaceuticals Inc. effective immediately on February 3, 2026. The company stated that her decision was not related to any disagreement over operations, policies, or practices, indicating a non-controversial departure.

Did Dr. Lori A. Birder’s resignation from LIPO involve any disagreement with the company?

The filing states that Dr. Lori A. Birder’s resignation from Lipella Pharmaceuticals’ Board was not due to any disagreement. This includes matters related to the company’s operations, policies, or practices, suggesting no underlying dispute or conflict prompted her decision to step down.

When did the Lipella Pharmaceuticals (LIPO) director resignation become effective?

Dr. Lori A. Birder’s resignation from the Lipella Pharmaceuticals Board of Directors became effective immediately on February 3, 2026. The company reported this effective date as the earliest event, framing the change as a prompt and formally acknowledged governance update.

Which SEC item does Lipella Pharmaceuticals (LIPO) reference for this board change?

Lipella Pharmaceuticals reported the resignation under Item 5.02, which covers departures of directors or certain officers and related arrangements. This item is used to disclose key leadership or governance changes that may be important for shareholders and market transparency.

Who signed the 8-K reporting the director resignation at Lipella Pharmaceuticals (LIPO)?

The 8-K was signed on behalf of Lipella Pharmaceuticals Inc. by Jonathan Kaufman, the company’s Chief Executive Officer. His signature, dated February 4, 2026, confirms the company’s authorization and formal submission of the disclosure regarding the board resignation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/04/2026 - 04:19 PM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 3, 2026

Lipella Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41575		20-2388040
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7800 Susquehanna St., Suite 505

Pittsburgh, PA

15208

(Address of registrant’s principal executive office)

(Zip code)

Registrant’s telephone number, including area code: (412) 894-1853

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 3, 2026, Lori A. Birder notified Lipella Pharmaceuticals Inc. (the “Company”) of her resignation from the Company’s Board of Directors, effective immediately. Dr. Birder’s decision to resign was not due to any disagreement with the Company on any matter relating to its operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 4, 2026	Lipella Pharmaceuticals Inc.

	By:	/s/ Jonathan Kaufman
		Name: Jonathan Kaufman Title: Chief Executive Officer

Source: View Original Filing on SEC EDGAR